Paloma Partners’s Mustang Bio MBIO Stock Holding History

Paloma Partners’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-120	Closed	-$285K	–	1993
2020 Q3	$285K	Buy	+120	New	+$296K	0.01%	1518

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's MBIO Position: Q4 2020 in Review

Paloma Partners sold out of Mustang Bio (MBIO) in Q4 2020, closing a stake of 120 shares — an estimated $285K sold.

Paloma Partners first reported a position in MBIO in Q3 2020 and held it in 1 quarter. The position peaked at $285K in Q3 2020. 93 funds tracked by Wall St. Rank hold MBIO as of Q4 2020.

Paloma Partners reported no remaining Mustang Bio position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 120 Mustang Bio shares in Q4 2020, an estimated $285K.
Paloma Partners first reported a position in Mustang Bio in Q3 2020 and held it in 1 quarter.
Paloma Partners's Mustang Bio position peaked at $285K in Q3 2020.
93 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.